Back to Directory

Michelle Haber

Email

mhaber@fhi360.org

Phone

919-321-3472

Institution

FHI 360

Title

Community Programs Associate

Address

FHI360
359 Blackwell St.
Ste 200
Durham, NC 27701

Request an Update

Affiliated Studies

IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy

DAIDS Number

TBD

Research Area

Complications & Comorbidities

Study Status

In Development

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Complications & Comorbidities

Study Status

Open to Accrual

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Treatment

Study Status

Enrolling

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

38530

Research Area

Complications & Comorbidities

Study Status

Enrolling

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Treatment

Study Status

In Development

Show All